Clinical and Experimental Reproductive Medicine

The Korean Society for Reproductive Medicine (대한생식의학회)
권호 표지
DOI QR코드

DOI QR Code

Clinical characteristics in Taiwanese women with polycystic ovary syndrome

  • Hsu, Ming-I (Department of Obstetrics and Gynecology, College of Medicine, Taipei Medical University)
  • Received : 2015.07.27
  • Accepted : 2015.08.15
  • Published : 2015.09.30
Download PDF
⟨ Previous Next ⟩

Abstract

Polycystic ovary syndrome (PCOS) is one of the most common hormonal endocrine disorders in women of reproductive age. It consists of a heterogeneous collection of signs and symptoms that together form a disorder spectrum. The diagnosis of PCOS is principally based on clinical and physical findings. The extent of metabolic abnormalities in women with PCOS varies with phenotype, body weight, age, and ethnicity. For general population, the prevalence of hyperandrogenism and oligomenorrhea decreases with age, while complications such as insulin resistance and other metabolic disturbances increase with age. Obese women with PCOS have a higher risk of developing oligomenorrhea, amenorrhea, hyperandrogenemia, insulin resistance, and lower luteinizing hormone (LH) to follicle stimulation hormone (FSH) ratios than non-obese women with PCOS. The LH to FSH ratio is a valuable diagnostic tool in evaluating Taiwanese women with PCOS, especially in the diagnosis of oligomenorrhea. Overweight/obesity is the major determinant of cardiovascular and metabolic disturbances in women of reproductive age.

Keywords

References

  1. Zawadski JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, editors. Polycystic ovary syndrome. Boston: Blackwell Scientific; 1992. p. 377-84.
  2. Balen A, Michelmore K. What is polycystic ovary syndrome? Are national views important? Hum Reprod 2002;17:2219-27. https://doi.org/10.1093/humrep/17.9.2219
  3. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome. Fertil Steril 2004;81:19-25.
  4. Azziz R. Controversy in clinical endocrinology: diagnosis of polycystic ovarian syndrome: the Rotterdam criteria are premature. J Clin Endocrinol Metab 2006;91:781-5. https://doi.org/10.1210/jc.2005-2153
  5. Hsu MI, Liou TH, Chou SY, Chang CY, Hsu CS. Diagnostic criteria for polycystic ovary syndrome in Taiwanese Chinese women: comparison between Rotterdam 2003 and NIH 1990. Fertil Steril 2007;88:727-9. https://doi.org/10.1016/j.fertnstert.2006.11.149
  6. Hart R, Norman R. Polycystic ovarian syndrome: prognosis and outcomes. Best Pract Res Clin Obstet Gynaecol 2006;20:751-78. https://doi.org/10.1016/j.bpobgyn.2006.04.006
  7. Chan CC, Ng EH, Tang OS, Lee CP, Ho PC. The prevalence of polycystic ovaries in Chinese women with a history of gestational diabetes mellitus. Gynecol Endocrinol 2006;22:516-20. https://doi.org/10.1080/09513590600906649
  8. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. Fertil Steril 2009;91:456-88. https://doi.org/10.1016/j.fertnstert.2008.06.035
  9. Chae SJ, Kim JJ, Choi YM, Hwang KR, Jee BC, Ku SY, et al. Clinical and biochemical characteristics of polycystic ovary syndrome in Korean women. Hum Reprod 2008;23:1924-31. https://doi.org/10.1093/humrep/den239
  10. Lam PM, Ma RC, Cheung LP, Chow CC, Chan JC, Haines CJ. Polycystic ovarian syndrome in Hong Kong Chinese women: patient characteristics and diagnostic criteria. Hong Kong Med J 2005; 11:336-41.
  11. DeUgarte CM, Bartolucci AA, Azziz R. Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. Fertil Steril 2005;83:1454-60. https://doi.org/10.1016/j.fertnstert.2004.11.070
  12. Yang JH, Weng SL, Lee CY, Chou SY, Hsu CS, Hsu MI. A comparative study of cutaneous manifestations of hyperandrogenism in obese and non-obese Taiwanese women. Arch Gynecol Obstet 2010;282:327-33. https://doi.org/10.1007/s00404-010-1485-2
  13. Cheung LP, Ma RC, Lam PM, Lok IH, Haines CJ, So WY, et al. Cardiovascular risks and metabolic syndrome in Hong Kong Chinese women with polycystic ovary syndrome. Hum Reprod 2008;23:1431-8. https://doi.org/10.1093/humrep/den090
  14. Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab 1999;84:165-9.
  15. Shi Y, Guo M, Yan J, Sun W, Zhang X, Geng L, et al. Analysis of clinical characteristics in large-scale Chinese women with polycystic ovary syndrome. Neuro Endocrinol Lett 2007;28:807-10.
  16. Chen X, Yang D, Li L, Feng S, Wang L. Abnormal glucose tolerance in Chinese women with polycystic ovary syndrome. Hum Reprod 2006;21:2027-32. https://doi.org/10.1093/humrep/del142
  17. Lee H, Oh JY, Sung YA, Chung H, Cho WY. The prevalence and risk factors for glucose intolerance in young Korean women with polycystic ovary syndrome. Endocrine 2009;36:326-32. https://doi.org/10.1007/s12020-009-9226-7
  18. Wei HJ, Young R, Kuo IL, Liaw CM, Chiang HS, Yeh CY. Prevalence of insulin resistance and determination of risk factors for glucose intolerance in polycystic ovary syndrome: a cross-sectional study of Chinese infertility patients. Fertil Steril 2009;91:1864-8. https://doi.org/10.1016/j.fertnstert.2008.02.168
  19. Taylor AE. Gonadotropin dysfunction in women with polycystic ovary syndrome. Fertil Steril 2006;86 Suppl 1:S12.
  20. Taylor AE, McCourt B, Martin KA, Anderson EJ, Adams JM, Schoenfeld D, et al. Determinants of abnormal gonadotropin secretion in clinically defined women with polycystic ovary syndrome. J Clin Endocrinol Metab 1997;82:2248-56.
  21. Turhan NO, Toppare MF, Seckin NC, Dilmen G. The predictive power of endocrine tests for the diagnosis of polycystic ovaries in women with oligoamenorrhea. Gynecol Obstet Invest 1999; 48:183-6. https://doi.org/10.1159/000010170
  22. Cho LW, Jayagopal V, Kilpatrick ES, Holding S, Atkin SL. The LH/FSH ratio has little use in diagnosing polycystic ovarian syndrome. Ann Clin Biochem 2006;43(Pt 3):217-9. https://doi.org/10.1258/000456306776865188
  23. Robinson S, Rodin DA, Deacon A, Wheeler MJ, Clayton RN. Which hormone tests for the diagnosis of polycystic ovary syndrome? Br J Obstet Gynaecol 1992;99:232-8. https://doi.org/10.1111/j.1471-0528.1992.tb14505.x
  24. Arroyo A, Laughlin GA, Morales AJ, Yen SS. Inappropriate gonadotropin secretion in polycystic ovary syndrome: influence of adiposity. J Clin Endocrinol Metab 1997;82:3728-33.
  25. Hsu MI, Liou TH, Liang SJ, Su HW, Wu CH, Hsu CS. Inappropriate gonadotropin secretion in polycystic ovary syndrome. Fertil Steril 2009;91:1168-74. https://doi.org/10.1016/j.fertnstert.2008.01.036
  26. Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes Relat Metab Disord 2002;26:883-96. https://doi.org/10.1038/sj.ijo.0801994
  27. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes 1989;38:1165-74. https://doi.org/10.2337/diab.38.9.1165
  28. Hoeger K. Obesity and weight loss in polycystic ovary syndrome. Obstet Gynecol Clin North Am 2001;28:85-97. https://doi.org/10.1016/S0889-8545(05)70187-X
  29. Martinez-Bermejo E, Luque-Ramirez M, Escobar-Morreale HF. Obesity and the polycystic ovary syndrome. Minerva Endocrinol 2007;32:129-40.
  30. Liou TH, Yang JH, Hsieh CH, Lee CY, Hsu CS, Hsu MI. Clinical and biochemical presentations of polycystic ovary syndrome among obese and nonobese women. Fertil Steril 2009;92:1960-5. https://doi.org/10.1016/j.fertnstert.2008.09.003
  31. Chun-Sen H, Chien-Hua W, Wan-Chun C, Ching-Tzu L, Chun-Jen C, Ming-I H. Obesity and insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol 2011;27:300-6. https://doi.org/10.3109/09513590.2010.488776
  32. Pasquali R, Gambineri A. Polycystic ovary syndrome: a multifaceted disease from adolescence to adult age. Ann N Y Acad Sci 2006;1092:158-74. https://doi.org/10.1196/annals.1365.014
  33. Hsu MI. Changes in the PCOS phenotype with age. Steroids 2013;78:761-6. https://doi.org/10.1016/j.steroids.2013.04.005
  34. Mansfield MJ, Emans SJ. Adolescent menstrual irregularity. J Reprod Med 1984;29:399-410.
  35. Birdsall MA, Farquhar CM. Polycystic ovaries in pre and postmenopausal women. Clin Endocrinol (Oxf) 1996;44:269-76. https://doi.org/10.1046/j.1365-2265.1996.676498.x
  36. Elting MW, Korsen TJ, Rekers-Mombarg LT, Schoemaker J. Women with polycystic ovary syndrome gain regular menstrual cycles when ageing. Hum Reprod 2000;15:24-8.
  37. Winters SJ, Talbott E, Guzick DS, Zborowski J, McHugh KP. Serum testosterone levels decrease in middle age in women with the polycystic ovary syndrome. Fertil Steril 2000;73:724-9. https://doi.org/10.1016/S0015-0282(99)00641-X
  38. Alsamarai S, Adams JM, Murphy MK, Post MD, Hayden DL, Hall JE, et al. Criteria for polycystic ovarian morphology in polycystic ovary syndrome as a function of age. J Clin Endocrinol Metab 2009;94:4961-70. https://doi.org/10.1210/jc.2009-0839
  39. Rowe JW, Minaker KL, Pallotta JA, Flier JS. Characterization of the insulin resistance of aging. J Clin Invest 1983;71:1581-7. https://doi.org/10.1172/JCI110914
  40. Rodriguez-Moran M, Guerrero-Romero F. Insulin resistance is independently related to age in Mexican women. J Endocrinol Invest 2003;26:42-8. https://doi.org/10.1007/BF03345121
  41. Bili H, Laven J, Imani B, Eijkemans MJ, Fauser BC. Age-related differences in features associated with polycystic ovary syndrome in normogonadotrophic oligo-amenorrhoeic infertile women of reproductive years. Eur J Endocrinol 2001;145:749-55. https://doi.org/10.1530/eje.0.1450749
  42. Johnstone EB, Rosen MP, Neril R, Trevithick D, Sternfeld B, Murphy R, et al. The polycystic ovary post-rotterdam: a common, age-dependent finding in ovulatory women without metabolic significance. J Clin Endocrinol Metab 2010;95:4965-72. https://doi.org/10.1210/jc.2010-0202
  43. Pavlik EJ, DePriest PD, Gallion HH, Ueland FR, Reedy MB, Kryscio RJ, et al. Ovarian volume related to age. Gynecol Oncol 2000;77: 410-2. https://doi.org/10.1006/gyno.2000.5783
  44. Wallace WH, Kelsey TW. Ovarian reserve and reproductive age may be determined from measurement of ovarian volume by transvaginal sonography. Hum Reprod 2004;19:1612-7. https://doi.org/10.1093/humrep/deh285
  45. Gosden RG, Faddy MJ. Ovarian aging, follicular depletion, and steroidogenesis. Exp Gerontol 1994;29:265-74. https://doi.org/10.1016/0531-5565(94)90006-X
  46. Kwee J, Schats R, McDonnell J, Themmen A, de Jong F, Lambalk C. Evaluation of anti-Mullerian hormone as a test for the prediction of ovarian reserve. Fertil Steril 2008;90:737-43. https://doi.org/10.1016/j.fertnstert.2007.07.1293
  47. Lin YH, Chiu WC, Wu CH, Tzeng CR, Hsu CS, Hsu MI. Antimullerian hormone and polycystic ovary syndrome. Fertil Steril 2011;96: 230-5. https://doi.org/10.1016/j.fertnstert.2011.04.003
  48. Carmina E, Campagna AM, Lobo RA. A 20-year follow-up of young women with polycystic ovary syndrome. Obstet Gynecol 2012;119(2 Pt 1):263-9. https://doi.org/10.1097/AOG.0b013e31823f7135
  49. Franks S. Polycystic ovary syndrome in adolescents. Int J Obes (Lond) 2008;32:1035-41. https://doi.org/10.1038/ijo.2008.61
  50. Liang SJ, Hsu CS, Tzeng CR, Chen CH, Hsu MI. Clinical and biochemical presentation of polycystic ovary syndrome in women between the ages of 20 and 40. Hum Reprod 2011;26:3443-9. https://doi.org/10.1093/humrep/der302
  51. Moran C, Knochenhauer E, Boots LR, Azziz R. Adrenal androgen excess in hyperandrogenism: relation to age and body mass. Fertil Steril 1999;71:671-4. https://doi.org/10.1016/S0015-0282(98)00536-6
  52. Panidis D, Tziomalos K, Macut D, Delkos D, Betsas G, Misichronis G, et al. Cross-sectional analysis of the effects of age on the hormonal, metabolic, and ultrasonographic features and the prevalence of the different phenotypes of polycystic ovary syndrome. Fertil Steril 2012;97:494-500. https://doi.org/10.1016/j.fertnstert.2011.11.041
  53. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009;120:1640-5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644
  54. Taverna MJ, Martinez-Larrad MT, Frechtel GD, Serrano-Rios M. Lipid accumulation product: a powerful marker of metabolic syndrome in healthy population. Eur J Endocrinol 2011;164:559-67. https://doi.org/10.1530/EJE-10-1039
  55. Pilote L, Dasgupta K, Guru V, Humphries KH, McGrath J, Norris C, et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 2007;176:S1-44.
  56. Kauffman RP, Baker TE, Baker VM, DiMarino P, Castracane VD. Endocrine and metabolic differences among phenotypic expressions of polycystic ovary syndrome according to the 2003 Rotterdam consensus criteria. Am J Obstet Gynecol 2008;198:670. e1-7. https://doi.org/10.1016/j.ajog.2008.01.037
  57. Legro RS, Chiu P, Kunselman AR, Bentley CM, Dodson WC, Dunaif A. Polycystic ovaries are common in women with hyperandrogenic chronic anovulation but do not predict metabolic or reproductive phenotype. J Clin Endocrinol Metab 2005;90:2571-9. https://doi.org/10.1210/jc.2004-0219
  58. Shroff R, Syrop CH, Davis W, Van Voorhis BJ, Dokras A. Risk of metabolic complications in the new PCOS phenotypes based on the Rotterdam criteria. Fertil Steril 2007;88:1389-95. https://doi.org/10.1016/j.fertnstert.2007.01.032
  59. Welt CK, Gudmundsson JA, Arason G, Adams J, Palsdottir H, Gudlaugsdottir G, et al. Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. J Clin Endocrinol Metab 2006;91:4842-8. https://doi.org/10.1210/jc.2006-1327
  60. Tzeng CR, Chang YC, Chang YC, Wang CW, Chen CH, Hsu MI. Cluster analysis of cardiovascular and metabolic risk factors in women of reproductive age. Fertil Steril 2014;101:1404-10. https://doi.org/10.1016/j.fertnstert.2014.01.023
  61. Wild RA, Grubb B, Hartz A, Van Nort JJ, Bachman W, Bartholomew M. Clinical signs of androgen excess as risk factors for coronary artery disease. Fertil Steril 1990;54:255-9. https://doi.org/10.1016/S0015-0282(16)53699-1
  62. Wakabayashi I. Age-dependent influence of gender on the association between obesity and a cluster of cardiometabolic risk factors. Gend Med 2012;9:267-77. https://doi.org/10.1016/j.genm.2012.05.004
  63. Khader YS, Batieha A, Jaddou H, Batieha Z, El-Khateeb M, Ajlouni K. Factor analysis of cardiometabolic risk factors clustering in children and adolescents. Metab Syndr Relat Disord 2011;9:151-6. https://doi.org/10.1089/met.2010.0097

Cited by

  1. Effect of IGF-I and TNF-α on intensification of steroid pathways in women with PCOS phenotypes are not identical. Enhancement of progesterone pathway in women with PCOS increases the concentrati vol.32, pp.9, 2015, https://doi.org/10.3109/09513590.2016.1159672
  2. New Insights into mTOR Signal Pathways in Ovarian-Related Diseases: Polycystic Ovary Syndrome and Ovarian Cancer vol.17, pp.12, 2016, https://doi.org/10.22034/apjcp.2016.17.12.5087
  3. Prevalence of Polycystic Ovary Syndrome in Nigerian Women with Infertility: A Prospective Study of the Three Assessment Criteria vol.8, pp.12, 2015, https://doi.org/10.4236/ojog.2018.812112
  4. Increased risk of fractures in patients with polycystic ovary syndrome: a nationwide population-based retrospective cohort study vol.36, pp.6, 2015, https://doi.org/10.1007/s00774-017-0894-8
  5. The prescription patterns of traditional Chinese medicine for women with polycystic ovary syndrome in Taiwan : A nationwide population-based study vol.98, pp.24, 2019, https://doi.org/10.1097/md.0000000000015890
  6. Increased Risk of Polycystic Ovary Syndrome and It’s Comorbidities in Women with Autoimmune Thyroid Disease vol.17, pp.7, 2020, https://doi.org/10.3390/ijerph17072422